Switch to:
Also traded in: Austria, Brazil, Chile, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.80
NAS:GILD's Cash-to-Debt is ranked lower than
87% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:GILD: 0.80 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GILD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.56 Max: 4122.75
Current: 0.8
0.15
4122.75
Equity-to-Asset 0.38
NAS:GILD's Equity-to-Asset is ranked lower than
83% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:GILD: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:GILD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.62 Max: 0.98
Current: 0.38
0.21
0.98
Debt-to-Equity 1.16
NAS:GILD's Debt-to-Equity is ranked lower than
90% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:GILD: 1.16 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:GILD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.35 Max: 2.96
Current: 1.16
0
2.96
Interest Coverage 15.88
NAS:GILD's Interest Coverage is ranked lower than
82% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:GILD: 15.88 )
Ranked among companies with meaningful Interest Coverage only.
NAS:GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 34.31 Max: 165.23
Current: 15.88
11.11
165.23
Piotroski F-Score: 5
Altman Z-Score: 4.03
Beneish M-Score: -2.92
WACC vs ROIC
6.87%
40.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 57.84
NAS:GILD's Operating Margin % is ranked higher than
97% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:GILD: 57.84 )
Ranked among companies with meaningful Operating Margin % only.
NAS:GILD' s Operating Margin % Range Over the Past 10 Years
Min: 40.39  Med: 50.27 Max: 68
Current: 57.84
40.39
68
Net Margin % 42.90
NAS:GILD's Net Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:GILD: 42.90 )
Ranked among companies with meaningful Net Margin % only.
NAS:GILD' s Net Margin % Range Over the Past 10 Years
Min: 26.72  Med: 37.34 Max: 55.48
Current: 42.9
26.72
55.48
ROE % 64.68
NAS:GILD's ROE % is ranked higher than
99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:GILD: 64.68 )
Ranked among companies with meaningful ROE % only.
NAS:GILD' s ROE % Range Over the Past 10 Years
Min: 29.75  Med: 50.37 Max: 106.64
Current: 64.68
29.75
106.64
ROA % 21.69
NAS:GILD's ROA % is ranked higher than
97% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:GILD: 21.69 )
Ranked among companies with meaningful ROA % only.
NAS:GILD' s ROA % Range Over the Past 10 Years
Min: 13.45  Med: 29.12 Max: 42.28
Current: 21.69
13.45
42.28
ROC (Joel Greenblatt) % 601.08
NAS:GILD's ROC (Joel Greenblatt) % is ranked higher than
98% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:GILD: 601.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:GILD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 161.64  Med: 183.96 Max: 601.08
Current: 601.08
161.64
601.08
3-Year Revenue Growth Rate 50.20
NAS:GILD's 3-Year Revenue Growth Rate is ranked higher than
87% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:GILD: 50.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:GILD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 41.7 Max: 162.8
Current: 50.2
0
162.8
3-Year EBITDA Growth Rate 70.30
NAS:GILD's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:GILD: 70.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GILD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -29.8  Med: 38.05 Max: 116.7
Current: 70.3
-29.8
116.7
3-Year EPS without NRI Growth Rate 76.40
NAS:GILD's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:GILD: 76.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:GILD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.7  Med: 30.35 Max: 143.5
Current: 76.4
-19.7
143.5
GuruFocus has detected 4 Warning Signs with Gilead Sciences Inc $NAS:GILD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GILD's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GILD Guru Trades in Q3 2016

First Eagle Investment 49,700 sh (+220.65%)
Jeremy Grantham 1,165,716 sh (+175.52%)
Jim Simons 1,947,048 sh (+80.39%)
Jeff Auxier 4,782 sh (+60.36%)
Jerome Dodson 350,000 sh (+32.08%)
Zeke Ashton 25,000 sh (+16.28%)
Murray Stahl 11,550 sh (+14.93%)
Lee Ainslie 7,880 sh (+12.25%)
John Rogers 1,532,528 sh (+6.18%)
T Rowe Price Equity Income Fund 1,425,000 sh (+3.64%)
Eaton Vance Worldwide Health Sciences Fund 635,263 sh (+94.21%)
Ronald Muhlenkamp 7,500 sh (unchged)
Julian Robertson 38,511 sh (unchged)
First Eagle Investment 300 sh (unchged)
Dodge & Cox 3,750 sh (unchged)
John Burbank 5,000,000 sh (unchged)
David Carlson 730,000 sh (unchged)
Ken Fisher 444,529 sh (-0.44%)
John Buckingham 62,994 sh (-1.03%)
Ronald Muhlenkamp 214,495 sh (-1.15%)
David Dreman 21,855 sh (-3.06%)
Pioneer Investments 3,293,651 sh (-4.95%)
Joel Greenblatt 923,534 sh (-9.11%)
Ray Dalio 315,272 sh (-15.85%)
NWQ Managers 81,896 sh (-24.38%)
Mario Gabelli 12,414 sh (-65.34%)
Steven Cohen 141,000 sh (-78.61%)
Paul Tudor Jones 2,800 sh (-79.64%)
John Burbank 3,224 sh (-99.56%)
» More
Q4 2016

GILD Guru Trades in Q4 2016

Tom Gayner 14,000 sh (New)
Paul Tudor Jones 11,401 sh (+307.18%)
Jim Simons 5,274,948 sh (+170.92%)
Jerome Dodson 490,000 sh (+40.00%)
Jeff Auxier 5,477 sh (+14.53%)
Murray Stahl 13,000 sh (+12.55%)
Joel Greenblatt 1,025,203 sh (+11.01%)
Lee Ainslie 8,520 sh (+8.12%)
John Rogers 1,584,199 sh (+3.37%)
Ken Fisher 455,496 sh (+2.47%)
Mario Gabelli 12,414 sh (unchged)
Ronald Muhlenkamp 14,800 sh (unchged)
Julian Robertson 38,511 sh (unchged)
T Rowe Price Equity Income Fund 1,425,000 sh (unchged)
First Eagle Investment 300 sh (unchged)
First Eagle Investment 49,700 sh (unchged)
David Carlson 730,000 sh (unchged)
Steven Cohen Sold Out
John Burbank Sold Out
Ronald Muhlenkamp 212,995 sh (-0.70%)
David Dreman 20,724 sh (-5.18%)
John Buckingham 59,446 sh (-5.63%)
Dodge & Cox 3,250 sh (-13.33%)
Zeke Ashton 21,000 sh (-16.00%)
Pioneer Investments 2,722,308 sh (-17.35%)
Jeremy Grantham 874,684 sh (-24.97%)
NWQ Managers 61,056 sh (-25.45%)
Ray Dalio 80,272 sh (-74.54%)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (-13.41%)
» More
Q1 2017

GILD Guru Trades in Q1 2017

Charles Brandes 108,756 sh (New)
John Hussman 50,000 sh (New)
Steven Cohen 566,100 sh (New)
Tom Gayner 27,000 sh (+92.86%)
Paul Tudor Jones 20,709 sh (+81.64%)
T Rowe Price Equity Income Fund 2,560,000 sh (+79.65%)
Jim Simons 7,707,248 sh (+46.11%)
Jerome Dodson 601,000 sh (+22.65%)
Jeff Auxier 6,677 sh (+21.91%)
First Eagle Investment 59,700 sh (+20.12%)
Joel Greenblatt 1,212,036 sh (+18.22%)
John Rogers 1,800,201 sh (+13.63%)
Mario Gabelli 14,080 sh (+13.42%)
Lee Ainslie 9,460 sh (+11.03%)
John Buckingham 63,635 sh (+7.05%)
Ronald Muhlenkamp 225,725 sh (+5.98%)
Murray Stahl 13,600 sh (+4.62%)
Ronald Muhlenkamp 28,600 sh (unchged)
Julian Robertson 38,511 sh (unchged)
First Eagle Investment 300 sh (unchged)
Dodge & Cox 3,250 sh (unchged)
Steven Cohen 28,700 sh (unchged)
David Carlson 730,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (unchged)
Zeke Ashton Sold Out
Ray Dalio Sold Out
Ken Fisher 451,634 sh (-0.85%)
David Dreman 20,174 sh (-2.65%)
NWQ Managers 52,811 sh (-13.50%)
Pioneer Investments 1,898,063 sh (-30.28%)
Jeremy Grantham 37,400 sh (-95.72%)
» More
Q2 2017

GILD Guru Trades in Q2 2017

Manning & Napier Advisors, Inc 214,432 sh (New)
Lee Ainslie 24,760 sh (+161.73%)
Steven Cohen 1,272,910 sh (+124.86%)
Pioneer Investments 3,493,148 sh (+84.04%)
Jim Simons 10,407,848 sh (+35.04%)
T Rowe Price Equity Income Fund 3,270,900 sh (+27.77%)
Tom Gayner 33,000 sh (+22.22%)
John Rogers 2,090,813 sh (+16.14%)
Jerome Dodson 646,000 sh (+7.49%)
John Buckingham 67,601 sh (+6.23%)
Ken Fisher 460,155 sh (+1.89%)
Charles Brandes 110,720 sh (+1.81%)
Jeff Auxier 6,773 sh (+1.44%)
Mario Gabelli 14,080 sh (unchged)
First Eagle Investment 59,700 sh (unchged)
First Eagle Investment 300 sh (unchged)
Ronald Muhlenkamp 25,600 sh (unchged)
Dodge & Cox 3,250 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Steven Cohen 28,700 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 225,685 sh (-0.02%)
David Carlson 700,000 sh (-4.11%)
NWQ Managers 45,800 sh (-13.28%)
Joel Greenblatt 963,721 sh (-20.49%)
Murray Stahl 9,400 sh (-30.88%)
David Dreman 12,145 sh (-39.80%)
John Hussman 25,000 sh (-50.00%)
Jeremy Grantham 6,800 sh (-81.82%)
Eaton Vance Worldwide Health Sciences Fund 464,801 sh (-15.50%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
T Rowe Price Equity Income Fund 2017-06-30 Add 27.77%0.23%$64.12 - $71.92 $ 82.6424%3,270,900
John Rogers 2017-06-30 Add 16.14%0.24%$64.12 - $71.92 $ 82.6424%2,090,813
Joel Greenblatt 2017-06-30 Reduce -20.49%0.22%$64.12 - $71.92 $ 82.6424%963,721
Ken Fisher 2017-06-30 Add 1.89%$64.12 - $71.92 $ 82.6424%460,155
Ronald Muhlenkamp 2017-06-30 Reduce -0.02%$64.12 - $71.92 $ 82.6424%225,685
Charles Brandes 2017-06-30 Add 1.81%$64.12 - $71.92 $ 82.6424%110,720
NWQ Managers 2017-06-30 Reduce -13.28%0.01%$64.12 - $71.92 $ 82.6424%45,800
Tom Gayner 2017-06-30 Add 22.22%0.01%$64.12 - $71.92 $ 82.6424%33,000
David Dreman 2017-06-30 Reduce -39.80%0.31%$64.12 - $71.92 $ 82.6424%12,145
T Rowe Price Equity Income Fund 2017-03-31 Add 79.65%0.35%$65.59 - $76.38 $ 82.6418%2,560,000
John Rogers 2017-03-31 Add 13.63%0.17%$65.59 - $76.38 $ 82.6418%1,800,201
Joel Greenblatt 2017-03-31 Add 18.22%0.16%$65.59 - $76.38 $ 82.6418%1,212,036
Ken Fisher 2017-03-31 Reduce -0.85%$65.59 - $76.38 $ 82.6418%451,634
Ronald Muhlenkamp 2017-03-31 Add 5.98%0.27%$65.59 - $76.38 $ 82.6418%225,725
Charles Brandes 2017-03-31 New Buy0.11%$65.59 - $76.38 $ 82.6418%108,756
First Eagle Investment 2017-03-31 Add 20.12%$65.59 - $76.38 $ 82.6418%59,700
NWQ Managers 2017-03-31 Reduce -13.50%0.01%$65.59 - $76.38 $ 82.6418%52,811
Tom Gayner 2017-03-31 Add 92.86%0.02%$65.59 - $76.38 $ 82.6418%27,000
David Dreman 2017-03-31 Reduce -2.65%0.02%$65.59 - $76.38 $ 82.6418%20,174
Mario Gabelli 2017-03-31 Add 13.42%$65.59 - $76.38 $ 82.6418%14,080
John Rogers 2016-12-31 Add 3.37%0.04%$71.61 - $78.47 $ 82.6411%1,584,199
Joel Greenblatt 2016-12-31 Add 11.01%0.09%$71.61 - $78.47 $ 82.6411%1,025,203
Ken Fisher 2016-12-31 Add 2.47%$71.61 - $78.47 $ 82.6411%455,496
Ronald Muhlenkamp 2016-12-31 Reduce -0.70%0.04%$71.61 - $78.47 $ 82.6411%212,995
NWQ Managers 2016-12-31 Reduce -25.45%0.02%$71.61 - $78.47 $ 82.6411%61,056
David Dreman 2016-12-31 Reduce -5.18%0.05%$71.61 - $78.47 $ 82.6411%20,724
Tom Gayner 2016-12-31 New Buy0.02%$71.61 - $78.47 $ 82.6411%14,000
Dodge & Cox 2016-12-31 Reduce -13.33%$71.61 - $78.47 $ 82.6411%3,250
John Rogers 2016-09-30 Add 6.18%0.09%$76.89 - $88.55 $ 82.642%1,532,528
T Rowe Price Equity Income Fund 2016-09-30 Add 3.64%0.02%$76.89 - $88.55 $ 82.642%1,425,000
Joel Greenblatt 2016-09-30 Reduce -9.11%0.09%$76.89 - $88.55 $ 82.642%923,534
Ken Fisher 2016-09-30 Reduce -0.44%$76.89 - $88.55 $ 82.642%444,529
Ronald Muhlenkamp 2016-09-30 Reduce -1.15%0.08%$76.89 - $88.55 $ 82.642%214,495
NWQ Managers 2016-09-30 Reduce -24.38%0.04%$76.89 - $88.55 $ 82.642%81,896
First Eagle Investment 2016-09-30 Add 220.65%0.01%$76.89 - $88.55 $ 82.642%49,700
David Dreman 2016-09-30 Reduce -3.06%0.04%$76.89 - $88.55 $ 82.642%21,855
Mario Gabelli 2016-09-30 Reduce -65.34%0.01%$76.89 - $88.55 $ 82.642%12,414
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CELG, NAS:AMGN, NAS:BIIB, NAS:REGN, NAS:VRTX, NAS:ALXN, NAS:INCY, NAS:BMRN, NAS:KITE, NAS:EXEL, NAS:SGEN, NAS:IONS, NAS:ALNY, NAS:TSRO, NAS:BLUE, NAS:BIVV, NAS:UTHR, NAS:NBIX, NAS:JUNO, NAS:TECH » details
Traded in other countries:GILD.Austria, GILD34.Brazil, GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Headquarter Location:USA
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of the recently approved combination regimen Harvoni.

Top Ranked Articles about Gilead Sciences Inc

Novartis and the Future of Gene Therapy The company recently became the first to market a gene therapy for cancer
Gene therapy is now, finally, a new weapon in our arsenal against cancer partly thanks to, of all things, the HIV virus. The world’s first chimeric antigen receptor T-cell (CAR-T) treatment was approved by the Food and Drug Administration at the end of last month, a treatment developed by one Dr. Carl June at University of Pennsylvania in partnership with Novatris AG (NYSE:NVS). Read more...
Stock Score Reports for Chesapeake Energy, Ford, General Electric, Gilead Sciences and Snap Inc.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE
UQM Technologies, Kite Pharma Jump on Monday Kite, Gilead gain on acquisition news
The U.S. stock market opened mixed with investors looking to the impact of Hurricane Harvey. Read more...
Pioneer Investments Buys Citigroup, Berkshire, Gilead The guru's largest 2nd-quarter investments
Pioneer Investments (TradesPortfolio) operates in wide areas of investment vehicles – mutual funds, single manager hedge funds, funds of hedge funds, structured products, segregated and managed accounts, institutional funds. During the second quarter the firm bought shares in the following stocks: Read more...
9 Stocks Tom Gayner Keeps Buying The guru bought these stocks in the last 2 quarters
Markel's Tom Gayner (Trades, Portfolio) bought the following stocks in both the first and second quarters of 2017:  Read more...
Gilead Rises After Increasing Product Sales Guidance Company hints at possible revenue rebound by end of year
Gilead Sciences Inc. (NASDAQ:GILD), a research-based biopharmaceutical company, increased its full-year guidance even though second-quarter product sales dropped $0.7 billion from the prior-year quarter. Read more...
Options trade ideas for ANI Pharmaceuticals, Facebook, Gilead Sciences, Hilton Worldwide and Shutterfly offer returns of 21% or more!
T. Rowe Price Buying Philip Morris, Gilead, Wells Fargo The fund's largest buys of the last 2 quarters
T Rowe Price Equity Income Fund (TradesPortfolio) owns a portfolio of $21.390 billion and composed of 101 stocks. In both the second and first quarters the guru bought shares in the following stocks: Read more...
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Here's a look at where the company's latest data fit into the hepatitis B space as a whole
Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) announced positive initial Phase II results for its new antiviral hepatitis B (HBV) treatment SB-9200. Shares have recorded all-time highs, up as much as 28% on the news. Read more...

Ratios

vs
industry
vs
history
PE Ratio 8.96
GILD's PE Ratio is ranked higher than
90% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. GILD: 8.96 )
Ranked among companies with meaningful PE Ratio only.
GILD' s PE Ratio Range Over the Past 10 Years
Min: 6.67  Med: 15.21 Max: 45.49
Current: 8.96
6.67
45.49
Forward PE Ratio 10.98
GILD's Forward PE Ratio is ranked higher than
85% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. GILD: 10.98 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 8.96
GILD's PE Ratio without NRI is ranked higher than
91% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. GILD: 8.96 )
Ranked among companies with meaningful PE Ratio without NRI only.
GILD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.67  Med: 15.14 Max: 45.49
Current: 8.96
6.67
45.49
Price-to-Owner-Earnings 8.52
GILD's Price-to-Owner-Earnings is ranked higher than
89% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. GILD: 8.52 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GILD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.68  Med: 13.64 Max: 74.51
Current: 8.52
5.68
74.51
PB Ratio 4.76
GILD's PB Ratio is ranked lower than
56% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. GILD: 4.76 )
Ranked among companies with meaningful PB Ratio only.
GILD' s PB Ratio Range Over the Past 10 Years
Min: 3.69  Med: 7.9 Max: 18.71
Current: 4.76
3.69
18.71
PS Ratio 3.85
GILD's PS Ratio is ranked higher than
80% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. GILD: 3.85 )
Ranked among companies with meaningful PS Ratio only.
GILD' s PS Ratio Range Over the Past 10 Years
Min: 2.95  Med: 6.31 Max: 12.5
Current: 3.85
2.95
12.5
Price-to-Free-Cash-Flow 8.18
GILD's Price-to-Free-Cash-Flow is ranked higher than
90% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. GILD: 8.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GILD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.66  Med: 15.19 Max: 48.02
Current: 8.18
5.66
48.02
Price-to-Operating-Cash-Flow 7.82
GILD's Price-to-Operating-Cash-Flow is ranked higher than
91% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. GILD: 7.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GILD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.41  Med: 14.23 Max: 45.09
Current: 7.82
5.41
45.09
EV-to-EBIT 6.69
GILD's EV-to-EBIT is ranked higher than
83% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. GILD: 6.69 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.2  Med: 11.1 Max: 209.2
Current: 6.69
-154.2
209.2
EV-to-EBITDA 6.26
GILD's EV-to-EBITDA is ranked higher than
82% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. GILD: 6.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.9  Med: 10.5 Max: 168
Current: 6.26
-189.9
168
EV-to-Revenue 3.99
GILD's EV-to-Revenue is ranked higher than
79% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. GILD: 3.99 )
Ranked among companies with meaningful EV-to-Revenue only.
GILD' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.1  Med: 6.5 Max: 13.1
Current: 3.99
3.1
13.1
PEG Ratio 0.17
GILD's PEG Ratio is ranked higher than
99% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. GILD: 0.17 )
Ranked among companies with meaningful PEG Ratio only.
GILD' s PEG Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.41 Max: 3.81
Current: 0.17
0.11
3.81
Shiller PE Ratio 18.24
GILD's Shiller PE Ratio is ranked higher than
88% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. GILD: 18.24 )
Ranked among companies with meaningful Shiller PE Ratio only.
GILD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.15  Med: 50.5 Max: 2078
Current: 18.24
14.15
2078
Current Ratio 3.37
GILD's Current Ratio is ranked lower than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. GILD: 3.37 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 7.01 Max: 57.67
Current: 3.37
1.09
57.67
Quick Ratio 3.20
GILD's Quick Ratio is ranked lower than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. GILD: 3.20 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 6.53 Max: 57.67
Current: 3.2
0.83
57.67
Days Inventory 140.16
GILD's Days Inventory is ranked lower than
59% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. GILD: 140.16 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 140.16  Med: 221.48 Max: 276.35
Current: 140.16
140.16
276.35
Days Sales Outstanding 57.42
GILD's Days Sales Outstanding is ranked higher than
63% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. GILD: 57.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.22  Med: 69.31 Max: 84.93
Current: 57.42
54.22
84.93
Days Payable 69.73
GILD's Days Payable is ranked higher than
66% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. GILD: 69.73 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 69.73  Med: 158.55 Max: 207.21
Current: 69.73
69.73
207.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.46
GILD's Dividend Yield % is ranked higher than
88% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. GILD: 2.46 )
Ranked among companies with meaningful Dividend Yield % only.
GILD' s Dividend Yield % Range Over the Past 10 Years
Min: 0.36  Med: 2.19 Max: 3.09
Current: 2.46
0.36
3.09
Dividend Payout Ratio 0.22
GILD's Dividend Payout Ratio is ranked higher than
85% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. GILD: 0.22 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GILD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.15 Max: 0.22
Current: 0.22
0.11
0.22
Forward Dividend Yield % 2.53
GILD's Forward Dividend Yield % is ranked higher than
89% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. GILD: 2.53 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.46
GILD's 5-Year Yield-on-Cost % is ranked higher than
71% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. GILD: 2.46 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GILD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.36  Med: 2.19 Max: 3.09
Current: 2.46
0.36
3.09
3-Year Average Share Buyback Ratio 5.10
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. GILD: 5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.6  Med: -3.9 Max: 6.1
Current: 5.1
-25.6
6.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 8.34
GILD's Price-to-Tangible-Book is ranked lower than
72% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. GILD: 8.34 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GILD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.51  Med: 8.52 Max: 214.73
Current: 8.34
1.51
214.73
Price-to-Intrinsic-Value-Projected-FCF 0.64
GILD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. GILD: 0.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GILD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 2.11 Max: 20.83
Current: 0.64
0.55
20.83
Price-to-Median-PS-Value 0.61
GILD's Price-to-Median-PS-Value is ranked higher than
79% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. GILD: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GILD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.88 Max: 30
Current: 0.61
0.49
30
Price-to-Peter-Lynch-Fair-Value 0.36
GILD's Price-to-Peter-Lynch-Fair-Value is ranked higher than
99% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. GILD: 0.36 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GILD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.29  Med: 0.92 Max: 9.13
Current: 0.36
0.29
9.13
Price-to-Graham-Number 1.82
GILD's Price-to-Graham-Number is ranked higher than
70% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. GILD: 1.82 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GILD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.56  Med: 3.4 Max: 15.78
Current: 1.82
1.56
15.78
Earnings Yield (Greenblatt) % 14.95
GILD's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. GILD: 14.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GILD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.1  Med: 7.6 Max: 18.8
Current: 14.95
-2.1
18.8
Forward Rate of Return (Yacktman) % 66.66
GILD's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. GILD: 66.66 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GILD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.2  Med: 7.05 Max: 71
Current: 66.66
1.2
71

More Statistics

Revenue (TTM) (Mil) $28,466.00
EPS (TTM) $ 9.22
Beta0.91
Short Percentage of Float1.43%
52-Week Range $63.76 - 86.27
Shares Outstanding (Mil)1,305.93

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 25,823 22,513 20,912 21,086
EPS ($) 8.67 7.37 7.05 7.19
EPS without NRI ($) 8.67 7.37 7.05 7.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-10.02%
Dividends per Share ($) 1.30 1.37 1.88
» More Articles for NAS:GILD

Headlines

Articles On GuruFocus.com
This Biotech Trend Could Indicate the Next 4-Year Bull Run Sep 14 2017 
Novartis and the Future of Gene Therapy Sep 14 2017 
5 Health Care Companies Gurus Are Buying Sep 05 2017 
Stock Score Reports for Chesapeake Energy, Ford, General Electric, Gilead Sciences and Snap Inc. Sep 01 2017 
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE Aug 31 2017 
UQM Technologies, Kite Pharma Jump on Monday Aug 28 2017 
10 Undervalued Stocks for the Enterprising Investor Aug 21 2017 
Pioneer Investments Buys Citigroup, Berkshire, Gilead Aug 08 2017 
9 Stocks Tom Gayner Keeps Buying Aug 01 2017 
Gilead Rises After Increasing Product Sales Guidance Jul 26 2017 

More From Other Websites
These Stocks Pay You to Own Them Sep 20 2017
See what the IHS Markit Score report has to say about Gilead Sciences Inc. Sep 20 2017
Should Value Investors Consider Gilead Sciences (GILD) Stock? Sep 19 2017
Your first trade for Tuesday, September 19 Sep 19 2017
Taking On Exposure to Innovative Biotechnology Stocks Sep 19 2017
Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade Sep 19 2017
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors Sep 19 2017
"Fast Money" final trades: AMD, INTC and more Sep 18 2017
Why Bellicum Pharmaceuticals Stock Is Rising Today Sep 18 2017
Benefitting from IBB’s Lower Expense Ratio Sep 18 2017
Gilead Sciences: Is The Kite Deal Too Little, Too Late? Sep 18 2017
The IBB Biotechnology ETF: The Drugs You Need? Sep 18 2017
3 Value Stocks for Smart Investors Sep 18 2017
3 Great Income Stocks That Could Double Their Dividends Sep 17 2017
AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share Sep 15 2017
After Gilead Sciences, More Biotech M&A? Sep 15 2017
3 Reasons Why Gilead Sciences Stock Is a Buy Now Sep 15 2017
3 Dividend Healthcare Stocks Sep 15 2017
Gilead Prices $3 Billion of Senior Unsecured Notes Sep 14 2017
ETFs with exposure to Gilead Sciences, Inc. : September 14, 2017 Sep 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}